Shire to announce third quarter 2016
results
Dublin, Ireland –
October 19, 2016 – Shire plc
(LSE: SHP, NASDAQ: SHPG), will announce third quarter 2016 earnings
on Tuesday November 1, 2016.
| Results press release
will be issued at: |
12:00 GMT / 08:00
EDT |
| Investor conference
call time: |
14:00 GMT / 10:00
EDT |
Live conference call for
investors:
Flemming Ornskov, MD, Chief Executive Officer and Jeff Poulton, Chief Financial Officer will host
the investor and analyst conference call at 10:00 EDT / 14:00
GMT.
The details of the conference call are as follows:
| UK dial in: |
0808 237 0030 or 020
3139 4830 |
| US dial in: |
1 866 928 7517 or 1
718 873 9077 |
| International Access
Numbers: |
http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Access_List.pdf |
| Password/Conf ID: |
42020034# |
| Live Webcast: |
http://investors.shire.com/quarterly-results/ |
Replay:
A replay of the presentation will be available for two weeks by
phone and by webcast for three months. Replay information can
be found on the Investor Relations section of Shire’s website at
http://investors.shire.com/.
For further information please
contact:
| Investor
Relations |
|
|
| Sarah Elton-Farr |
seltonfarr@shire.com |
+44 1256
894157 |
| Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
| Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
Notes to editors
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases and other highly specialized
conditions. We strive to develop best-in-class products, many of
which are available in more than 100 countries, across core
therapeutic areas including Hematology, Immunology, Neuroscience,
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
Internal Medicine / Endocrine and Hereditary Angioedema; and a
growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com